



Ghana COVID-19 Emergency Preparedness and Response Project (P173788)

AFRICA WEST | Ghana | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 4 | ARCHIVED on 24-Jan-2022 | ISR48518 |

Implementing Agencies: Ghana Health Services, Republic of Ghana, Ministry of Health

Key Dates**Key Project Dates**

Bank Approval Date: 02-Apr-2020

Effectiveness Date: 03-Apr-2020

Planned Mid Term Review Date: 29-Mar-2021

Actual Mid-Term Review Date: 12-Mar-2021

Original Closing Date: 30-Jun-2022

Revised Closing Date: 30-Jun-2023

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Ghana

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Emergency COVID-19 Response:(Cost \$336.86 M)

Strengthening Multi-sector, National Institutions and Platforms for Policy Development and Coordination of Prevention and Preparedness using One Health approach:(Cost \$9.40 M)

Community Engagement and Risk Communication:(Cost \$10.80 M)

Implementation management and monitoring and evaluation and project management:(Cost \$7.94 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Risk Rating	<input type="checkbox"/> High	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

Operational funds have continuously supported both immediate needs for COVID-19 emergency response, scaling up vaccination, and health systems strengthening with improved equity. The project resources were used to support the identification and testing of more than 2 million persons as of December 12, 2021. The laboratory capacity has been constantly increased to 41 in all the 16 regions and further expands with GeneXpert equipment in preparation for repeated surges. Case management is being performed at 42 treatment centers with increased ICU bed capacity from 44 to 129 in 10 out of 16 regions. The project is reaching out to the vulnerable, including more than 20,000 persons with disabilities, with psychological and medical care and protective gear. Routine health and nutrition services are being made up for the acute disruption at the onset of the COVID-19 pandemic. As of December 16, 2021, 9.2 percent of the total population were fully vaccinated.



MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

As of January 17, 2022, 87 MPA-projects had been approved with a total commitment of US\$4.2 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. Therefore, there are 86 MPA active operations. Fifty-eight (58) country projects or 67% of projects approved have reached 70-100% disbursement (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). Out of the 58 projects, 35 operations or 60% have disbursed over 90% of commitments. The projects are benefitting around 3.7 billion people or 50% of the global population. Of the 86 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 7 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-five (85) or 99% of projects approved are disbursing. **Total disbursements as of January 17, 2022, amounted to US\$3.30 billion or 78% of overall commitments.** Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. **Six parent projects have been restructured to include vaccine-related procurement.** Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Implementation continues to face challenges as several countries are still under different levels of lockdown or mobility restrictions, and counterparts and Bank teams are operating from home or partially from home. Also, countries are dealing with new waves of infections as the Omicron variant is spreading rapidly among populations. The variant which was first identified in South Africa and Botswana has been detected in more than 80 nations by mid-December. Many Bank teams continue to conduct implementation support missions virtually, which is challenging for both Bank teams and counterparts. This “virtual” world poses connectivity challenges as the internet is not reliable in many countries, especially IDA countries. Notwithstanding the challenges, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements attests to the strong implementation of the Bank’ response thanks to the commitment of counterparts supported by Bank country teams.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach (“Global COVID-19 MPA”) was approved by the Board on October 13, 2021. The AF-V is significantly expanding Bank support to client countries for COVID-19 vaccination, with the aim to support vaccination of 1 billion people globally. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG’s overall COVID-19 response.

As of January 17, 2022, the Bank has approved 83 operations to support vaccine procurement and rollout in 69 countries amounting to \$7.6 billion. The 83 AF-V operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 83 approved operations: (i) 45 are in Africa – 21 in AFE and 24 in AFW; (ii) 8 in East Asia; (iii) 9 in Europe and Central Asia; (iv) 6 in Latin America and the Caribbean; (v) 7 in Middle East and North Africa; and (vi) 8 in South Asia. Forty-three (43) projects are disbursing. Thirty new operations are under various stages of processing. **Total disbursements as of January 17, 2022, under these projects amount to US\$1.8 billion or 24% of overall commitments.** As



with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Seventy (70) loan/financing agreements have been signed. Also, sixty (60) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of lockdown or mobility restrictions and counterparts and Bank teams are operating from home. Countries are dealing with new waves of infections as the Omicron variant is spreading rapidly among populations. The variant, which was first identified in South Africa and Botswana, has been detected in more than 80 nations by mid-December 2021.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	☐ Substantial	☐ Moderate	☐ Moderate
Macroeconomic	☐ Substantial	☐ Substantial	☐ Substantial
Sector Strategies and Policies	☐ Moderate	☐ Moderate	☐ Moderate
Technical Design of Project or Program	☐ Moderate	☐ Moderate	☐ Moderate
Institutional Capacity for Implementation and Sustainability	☐ Substantial	☐ Substantial	☐ Moderate
Fiduciary	☐ High	☐ Substantial	☐ Substantial
Environment and Social	☐ Substantial	☐ Substantial	☐ Substantial
Stakeholders	☐ Low	☐ Low	☐ Low
Other	--	--	--
Overall	☐ Substantial	☐ High	☐ Substantial

Results

PDO Indicators by Objectives / Outcomes

Emergency COVID-19 Response				
▶ Diagnosed cases treated in the designated treatment centers per approved protocol (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	68.00	100.00	80.00
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023
Comments:	As of November 30, 2021, the total number of active cases on admission/home care was 699 out of which 26 cases classified as severe and three as critical. A cumulative of 1,209 deaths have been recorded. Cumulative number of recoveries stands at 129,042 out of 130,920 total confirmed cases.			



<input type="checkbox"/> Diagnosed cases treated in the designated treatment centers per approved protocol (by % female) (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	100.00	80.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	30-Jun-2023
► Designated acute healthcare facilities with isolation capacity (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	15.00	79.00	50.00
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023
► Confirmed COVID-19 cases that conducted contact tracing (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	60.00	100.00
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023
Comments:	The Government continues to implement enhanced surveillance and contact tracing. As of November 20, 2021, of 130,920 cumulative confirmed cases, 78,233 cases were detected through the enhanced contact tracing and 2,981 cases were among international travelers at the Kotoka International Airport (KIA).			
► Infected health workers to COVID-19 treated (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	94.00	100.00
Date	02-Apr-2020	02-Apr-2020	30-Sep-2021	30-Jun-2023
<input type="checkbox"/> Infected health workers to COVID-19 treated (by % female) (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	100.00	100.00
Date	02-Apr-2020	02-Apr-2020	30-Sep-2021	30-Jun-2023
► Population vaccinated, who are included in the target population groups defined in the National COVID-19 Vaccine Deployment Plan (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	9.20	41.60
Date	01-Mar-2021	01-Mar-2021	16-Dec-2021	30-Jun-2023
Comments:	As of November 20, 2021, 4.3 million people received at least one dose of COVID-19 vaccine and 1.3 million people were fully vaccinated, consisting of 6.6 percent of the total population.			



□ Proportion of females among those vaccinated (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	52.10	50.00
Date	01-Mar-2021	01-Mar-2021	03-Nov-2021	30-Jun-2023

Overall Comments

Four out of eight PDO indicators have been already achieved and maintain the good progress. Contract tracing was softened after the third wave of COVID-19 pandemic. Yet, as the festive season is approaching, the Government continues to implement enhanced surveillance and contact tracing, especially at the Kotoka International Airport (KIA) where the new variants were detected. The Government is recording outstanding progress in COVID-19 vaccination. While still 9.2 percent of the total population were fully vaccinated, 864,763 doses were administered in the December 2021 alone. With the influx of COVID-19 vaccines into the country with the arrival of 6 million doses in December 2021 alone, the COVID-19 vaccination coverage is expected to significantly increase in the coming six months.

Intermediate Results Indicators by Components

Emergency COVID-19 Response				
▶ Designated laboratories with COVID-19 diagnostic equipment, test kits and reagents (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	2.00	10.00	63.00	14.00
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023
Comments:	The result does not include health facilities with GeneXpert equipment.			
▶ Designated laboratories diagnosed suspected COVID-19 cases within 24 hrs (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	2.00	10.00	63.00	10.00
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023
▶ Referral system to care for COVID-19 patients prepared (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023



▶ Treatment centers completed with ICU beds and providing services (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	7.00	24.00	12.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	30-Jun-2023
▶ Cold chain system functional (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	62.70	62.70	100.00	100.00
Date	01-Mar-2021	01-Mar-2021	30-Sep-2021	30-Jun-2023
▶ People who have received essential health, nutrition, and population (HNP) services (Number, Corporate)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	13,649,140.00	34,800,000.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	31-Dec-2022
Comments:	The result presented is the cumulative number of OPD visits at the PHC facilities from January 2020 to September 2021.			
☐ People who have received essential health, nutrition, and population (HNP) services - Female (RMS requirement) (Number, Corporate Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	8,435,632.00	17,400,000.00
☐ Number of children immunized (Number, Corporate Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	1,206,807.00	2,475,000.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	31-Dec-2022
☐ Number of women and children who have received basic nutrition services (Number, Corporate Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	4,973,642.00	2,700,000.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	31-Dec-2022
☐ Number of deliveries attended by skilled health personnel (Number, Corporate Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target



Value	0.00	0.00	359,787.00	690,000.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	31-Dec-2022

Strengthening Multi-sector, National Institutions and Platforms

► Designated facilities for COVID-19 received monitoring and supportive supervision in preceding quarter (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	80.00
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023
Comments:	All designated facilities were visited by the Case Management Team during the quarter and a report was submitted.			

► Designated highly fuel-efficient, low-carbon fuels or electric powered vehicles procured (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	12.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	30-Jun-2023
Comments:	The procurement plan for highly fuel-efficient, low-carbon fuels was approved in the STEP. The procurement processes are underway.			

Community Engagement and Risk Communication

► People having adequate knowledge on Infection Prevention and Control (IPC) measures (Percentage, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	70.00	70.00	81.00	90.00
Date	01-Mar-2021	01-Mar-2021	30-Sep-2021	30-Jun-2023

□ Women having adequate knowledge on Infection Prevention and Control (IPC) measures (Percentage, Custom Breakdown)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	83.00	90.00
Date	01-Mar-2021	01-Mar-2021	30-Sep-2021	30-Jun-2023

► All the regions have functional COVID-19 information centers (Number) (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
--	----------	-------------------	------------------	------------



Value	2.00	16.00	16.00	16.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	30-Jun-2022
► People are willing to take up COVID-19 vaccination (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	83.00	80.00
Date	01-Mar-2021	01-Mar-2021	30-Sep-2021	30-Jun-2023
Comments:	The national survey showed 81 percent of men and 85 percent of women were willing to take COVID-19 vaccine.			
□ Women are willing to take up COVID-19 vaccination (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	85.00	80.00
Date	01-Mar-2021	01-Mar-2021	30-Sep-2021	30-Jun-2023

Implementation Management, Monitoring and Evaluation and Project Management				
► Quarterly reports with IDSR data submitted in a timely manner (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	951.00	90.00
Date	02-Apr-2020	30-Jun-2020	30-Sep-2021	30-Jun-2023
► Complaints received and addressed within one week through the project GRM (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	96.00	100.00
Date	02-Apr-2020	30-Oct-2020	30-Sep-2021	30-Jun-2023
Comments:	To date, the call centers received and responded to 134,850 calls and complaints with 96 percent complaint resolution rate.			

Performance-Based Conditions

Data on Financial Performance

Disbursements (by loan)




Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173788	IDA-66020	Effective	USD	35.00	35.00	0.00	33.86	1.92	95%
P173788	IDA-67950	Effective	USD	130.00	130.00	0.00	77.72	52.28	60%
P173788	IDA-69230	Effective	USD	200.00	200.00	0.00	60.97	139.03	30%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173788	IDA-66020	Effective	02-Apr-2020	03-Apr-2020	03-Apr-2020	30-Jun-2022	30-Jun-2022
P173788	IDA-67950	Effective	10-Nov-2020	12-Nov-2020	14-Dec-2020	30-Jun-2022	30-Jun-2022
P173788	IDA-69230	Effective	10-Jun-2021	13-Jul-2021	15-Jul-2021	30-Jun-2023	30-Jun-2023

Cumulative Disbursements



PBC Disbursement

PBC ID	PBC Type	Description	Coc	PBC Amount	Achievement Status	Disbursed amount in Coc	Disbursement % for PBC
--------	----------	-------------	-----	------------	--------------------	-------------------------	------------------------



Restructuring History

There has been no restructuring to date.

Related Project(s)

P174839-GHANA COVID-19 EMERGENCY PREPAREDNESS AND RESPONSE PROJECT ADDITIONAL FINANCING ,P176485-Ghana COVID-19 Emergency Preparedness and Response Project Second Additional Financing ,P178054-Ghana COVID-19 Emergency Preparedness and Response Project Third Additional Financing
